VENOUS THROMBOEMBOLISM IN MALIGNANT HEMATOLOGIC DISEASES (PILOT PROJECT)

Emilija Lazarova Trajkovska; Marijan Bosevski

Emilija Lazarova Trajkovska UC National Center for Cardiovascular Diseases, Faculty of Medicine, Ss Cyril and Methodius University in Skopje, North Macedonia
Marijan Bosevski UC National Center for Cardiovascular Diseases, Faculty of Medicine, Ss Cyril and Methodius University in Skopje, North Macedonia

Abstract

Introduction:Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a very common and potentially fatal disease. The incidence of VTE in cancer patients is about 4-7 times higher than in healthy individuals. Aim: The motive for conducting this prospective cohort clinical study is to gain our experience regarding the incidence of VTE in malignant hemopathies, the association of VTE with the stage of the underlying disease, the possible impact of primary treatment on the incidence of VTE and the clinical outcome of the underlying disease. Material and methods: This is a prospective cohort study involving 20 consecutive outpatients with malignant haemopathies. We conduct screening for deep vein thrombosis with Echo Color Doppler sonography. Results: The study included 20 patients with a mean age of 58.35 years, of whom 13(65%) were male and 7(35%) female.18 patients were diagnosed with lymphoma and two were diagnosed with multiple myeloma. In 8 patients (45%) DVT was found, with occlusion of femoral vein in 4 (45%) , popliteal vein in 3 (33%), 1 (11%) patient had DVT of the subclavian vein, and 1 (11%) of the cerebral vein (confirmed by CT). Conclusion: deep vein thrombosis is highly prevalent in patients with malignant haemopathies. Hospitalization, malignancy activity, and reception of therapy all contribute to the occurrence of venous thrombosis. Compressive ultrasound is a solid and sensitive tool for screening and diagnosis of deep vein thrombosis.

Keywords: malignant hemopathies, venous thromboembolism, anticoagulant therapy.

References

1. Fernandes CJ, Morinaga LTK, Alves JL Jr, Castro MA, Calderaro D, Jardim CVP, Souza R. Cancer-associated thrombosis: the when, how and why. Eur Respir Rev. 2019 Mar 27; 28(151):180119. doi: 10.1183/16000617.0119-2018. PMID: 30918022.
2. Donnellan E, Khorana AA. Cancer and Venous Thromboembolic Disease: A Review. Oncologist. 2017 Feb; 22(2):199-207. doi: 10.1634/theoncologist.2016-0214. Epub 2017 Feb 7. PMID: 28174293; PMCID: PMC5330704.
3. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007 Mar; 5(3):632-4. doi: 10.1111/j.1538-7836.2007.02374.x. PMID: 17319909.
4. Gervaso L, Dave H, Khorana AA. Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2021 Apr 20; 3(2):173-190. doi: 10.1016/j.jaccao.2021.03.001. PMID: 34396323; PMCID: PMC8352228.
5. Gade IL, Brækkan S, Næss IA, Hansen JB, Rosendaal F, Cannegieter S, Overvad K, Jensvoll H, Hammerstrøm J, Gran OV, Tjønneland A, Kristensen SR, Severinsen MT.
6. Epidemiologyof venous thromboembolism in hematological cancers:The Scandinavian Thrombosis and Cancer (STAC) cohort.Thromb Res.2017; 158:157- 160.
7. Caruso V,Di Castelnuovo A,Meschengieser S,Lazzari MA,de Gaetano G,Storti S, Iacoviello L,Donati MB.Thrombotic complications in adult patients ith lymphoma:a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events.Blood.2010 Jul 1; 115(26):5322-8. doi:10.1182/blood-2010-01-258624.
8. Lyman GH. Venous thromboembolism in the patient with cancer.focus on burden of disease and benefit of thromboprophylaxis. Cancer. 2011; 117 (7): 1334-1349.
9. Chee CE, Ashrani AA, Marks RS, et al. Predictors of venous thromboembolism, reccurence and bleeding among active cancer patients: a population – based cohort study. Blood.2014; 123(25):3972-3978.
10. Goodacre S, Sampson F, Thomas S, van Beek E, Sutton A.Systematic review and meta-analysis of the diagnostic accuracy of ultrasonography for deep vein thrombosis.BMC Med Imaging. 2005 Oct 3;5:6.
11. Pabinger I, Riedl J. Direct oral anticoagulants: now also for prevention and treatment of cancer-associated venous thromboembolism? Hematology 2017 p136-143.
12. Spyropoulos AC, Anderson FA Jr, FitzGerald G, Decousus H, Pini M, Chong BH, Zotz RB, Bergmann JF, Tapson V, Froehlich JB, Monreal M, Merli GJ, Pavanello R, Turpie AGG, Nakamura M, Piovella F, Kakkar AK, Spencer FA; IMPROVE Investigators. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011 Sep; 140(3):706-714. doi: 10.1378/chest.10-1944. Epub 2011 Mar 24. PMID: 21436241.
13. Bosevski M, Trajkovska EL, Krstevski G, Aliu F, Salkoski S, Matkova D, Trajkovski A, Bojovski I, Mitevska I, Stavrik S, Candelera RO, Pavkovic M. Cancer - Associated Thrombosis - A Study of Cases. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2021 Oct 26; 42(2):89-97. doi: 10.2478/prilozi-2021-0025. PMID: 34699704.
14. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falanga A; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015 Feb 20; 33(6):654-6. doi: 10.1200/JCO.2014.59.7351. Epub 2015 Jan 20. PMID: 25605844; PMCID: PMC4881372.
15. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020 Feb 10; 38(5):496-520. doi: 10.1200/JCO.19.01461. Epub 2019 Aug 5. PMID: 31381464.